Mercury takes a tumble
Profits soared in the last quarter, but shares of Mercury Computer, which has carved out a comfortable niche as a supplier of digital components to radiology OEMs, tumbled on news that the future will not be so bright. About 71% of company revenues come
Profits soared in the last quarter, but shares of Mercury Computer, which has carved out a comfortable niche as a supplier of digital components to radiology OEMs, tumbled on news that the future will not be so bright. About 71% of company revenues come from defense electronics. Medical imaging accounts for about 17%. Revenues for defense products leaped in the last quarter, reported April 17, but looking to the future, orders are down across the board. Medical imaging has been hit particularly hard, with sagging results in the third quarter, ended March 31. Revenues for medical imaging were down 43% compared with the prior year's 3Q performance of $14.3 million. For the first nine months of fiscal 2003, medical imaging revenues were $28.4 million, compared with $34.8 million for the same period of fiscal 2002. The drop was due to continued reductions in CT-related revenues as customers introduce CT models that do not contain the Mercury products. Mercury shipments of CT components are expected to cease altogether by the end of the fourth quarter.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
